Invitrogen™ LeukoLOCK™ Total RNA Isolation System

Description

The LeukoLOCK™ Total RNA Isolation System is an innovative method for cellular fractionation of whole blood and total RNA stabilization and extraction from the leukocyte population. The kit is comprised of a LeukoLOCK Fractionation & Stabilization Kit (also available separately; Cat. No. AM1933) and a LeukoLOCK Total RNA Isolation Kit.

The LeukoLOCK system is optimized for use with human blood. Blood is a storehouse of cellular information; however, the presence of globin mRNA in RNA prepared from whole blood can interfere with downstream expression profiling applications. The LeukoLOCK system employs filter-based leukocyte-depletion technology to isolate leukocytes from whole blood and RNAlater™ solution to stabilize the cells on the filter. By excluding red blood cells, the RNA that is purified from captured leukocytes is inherently depleted of globin mRNA, which improves sample utility for expression profiling and other applications.

Leukocyte Capture and Stabilization
A 9–10 mL sample of anticoagulated blood is passed through a LeukoLOCK filter, which captures the total leukocyte population while eliminating red blood cells (including reticulocytes), platelets, and plasma. After rinsing with phosphate-buffered saline, the filter is flushed with RNAlater solution to stabilize the RNA in the captured leukocytes . The RNA can be isolated immediately, or stabilized cells can be maintained for several days at room temperature or for longer periods at –20°C or –80°C.

RNA Isolation
Purification of the RNA is done by first disrupting the captured cells in a guanidinium thiocyanate–based solution that releases the RNA while simultaneously inactivating nucleases. The cell lysate is collected and briefly treated with Proteinase K. RNA is then purified from the lysate using MagMAX magnetic bead-based technology for washing, followed by DNase treatment (with TURBO DNase™) and final clean-up.

Expression Studies
Both quantitative RT-PCR and microarray expression studies have validated the suitability of the purified RNA for reliable transcriptome profiling. Compared to RNA processed with a commonly used blood RNA isolation procedure, RNA isolated with the LeukoLOCK system produces longer median aRNA after amplification and higher percent present calls without requiring additional post-extraction steps to remove globin mRNA. Since globin aRNA represents 25–40% of the aRNA peak from whole blood total RNA, the yield of total RNA is understandably lower with methods that deplete unwanted globin transcripts. RNA amplified after LeukoLOCK purification offers greater array sensitivity due to the dramatic reduction in competing globin transcripts.

Kit Yields
Recovery varies from donor to donor, but is typically 10–20 μg of RNA per 9–10mL of whole blood. RNA recovered using the LeukoLOCK system contains less than one-tenth the amount of reticulocyte-derived alpha- and beta-globin mRNAs present in typical RNA samples from unfractionated whole blood.

• Fractionates leukocytes from whole blood in minutes
• Extracts total RNA from leukocytes
• No additional globin reduction steps required
• Stabilizes RNA to preserve expression profile
• Preserves leukocytes at room temperature for days

Not high-throughput compatible (Manual)